"Herpesvirus 1, Human" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of SIMPLEXVIRUS causing most forms of non-genital herpes simplex in humans. Primary infection occurs mainly in infants and young children and then the virus becomes latent in the dorsal root ganglion. It then is periodically reactivated throughout life causing mostly benign conditions.
| Descriptor ID |
D018259
|
| MeSH Number(s) |
B04.280.382.100.750.390
|
| Concept/Terms |
Herpesvirus 1, Human- Herpesvirus 1, Human
- Herpesvirus 1 (alpha), Human
- Human Herpesvirus 1
- HHV-1
- Herpes Simplex Virus Type 1
- Herpes Simplex Virus 1
- HSV-1
|
Below are MeSH descriptors whose meaning is more general than "Herpesvirus 1, Human".
Below are MeSH descriptors whose meaning is more specific than "Herpesvirus 1, Human".
This graph shows the total number of publications written about "Herpesvirus 1, Human" by people in this website by year, and whether "Herpesvirus 1, Human" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 1 | 1 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 4 | 1 | 5 |
| 2003 | 1 | 2 | 3 |
| 2004 | 5 | 3 | 8 |
| 2005 | 3 | 0 | 3 |
| 2006 | 6 | 0 | 6 |
| 2007 | 4 | 1 | 5 |
| 2008 | 1 | 0 | 1 |
| 2009 | 4 | 1 | 5 |
| 2010 | 1 | 0 | 1 |
| 2011 | 5 | 2 | 7 |
| 2012 | 2 | 1 | 3 |
| 2014 | 1 | 2 | 3 |
| 2015 | 2 | 2 | 4 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 2 | 3 |
| 2019 | 0 | 2 | 2 |
| 2020 | 1 | 3 | 4 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Herpesvirus 1, Human" by people in Profiles.
-
Promises of oncolytic viral therapy for adult and children with brain glioma. Curr Opin Oncol. 2023 11 01; 35(6):529-535.
-
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. J Clin Oncol. 2023 01 20; 41(3):528-540.
-
A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. Sci Rep. 2021 11 15; 11(1):22242.
-
Herpes Simplex Virus 1 MicroRNA miR-H8 Is Dispensable for Latency and Reactivation In Vivo. J Virol. 2021 01 28; 95(4).
-
Characterization of the Herpes Simplex Virus (HSV) Tegument Proteins That Bind to gE/gI and US9, Which Promote Assembly of HSV and Transport into Neuronal Axons. J Virol. 2020 11 09; 94(23).
-
Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity. Clin Cancer Res. 2021 01 15; 27(2):542-553.
-
Deletion of Herpes Simplex Virus 1 MicroRNAs miR-H1 and miR-H6 Impairs Reactivation. J Virol. 2020 07 16; 94(15).
-
Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer. JAMA Netw Open. 2020 07 01; 3(7):e207911.
-
Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size. Ann Surg Oncol. 2019 Dec; 26(13):4633-4641.
-
National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. Cancer. 2019 08 15; 125(16):2732-2746.